Sorafenib , marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma . It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma , and has since performed well in Phase III trials. It is a small molecular inhibitor of Raf kinase, PDGF , VEGF receptor 2 & 3 kinases and c Kit the receptor for...